Since AAT-rich plasma is administered to individuals with AATD and some other conditions such as diabetes type 1 and influenza, it is plausible to consider it as a new treatment for severe COVID-19 patients. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.